Please login to the form below

Stephen Whitehead appointed as ABPI CEO

Stephen Whitehead will take up the role of ABPI CEO with effect from June 1, taking over from Richard Barker who steps down as director general on May 25

The Association of the British Pharmaceutical Industry (ABPI) has announced Stephen Whitehead will take up the role of CEO with effect from June 1, taking over from Richard Barker who steps down as director general on May 25.

ABPI president Simon Jose said: "The Board of Management is delighted by this appointment. We are in a time of dynamic change for the health service, the economy, our industry and the ABPI itself. As chief executive, Stephen brings skills and experiences that will enable us to meet the challenges ahead with energy and creativity."

It will be essential to work collaboratively and flexibly to realise the value of medicines in contributing to patients' well-being and to promote the vital importance of this industry in the UK

Whitehead joins the ABPI from Prudential PLC where he held the role of group communications director. He has previously held senior leadership roles at Barclays PLC and Allied Domecq PLC.

Earlier in his career, Whitehead spent ten years at GlaxoSmithKline (GSK) and Eli Lilly at UK, European and international level.

Whitehead has considerable experience working in regulated industries, has led significant change and modernisation programmes and has extensive experience of developing high performing teams.

Commenting on his appointment, Whitehead said: "In today's changing environment and demanding economic circumstances it will be essential to work collaboratively and flexibly to realise the value of medicines in contributing to patients' well-being and to promote the vital importance of this industry in the UK, a traditional home of discovery, innovation and research and development."